SI-BONE, Inc. (NASDAQ:SIBN) Insider Sells $46,850.65 in Stock

SI-BONE, Inc. (NASDAQ:SIBN) insider Anthony J. Recupero sold 3,311 shares of the firm’s stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $14.15, for a total value of $46,850.65. Following the completion of the transaction, the insider now owns 284,555 shares in the company, valued at approximately $4,026,453.25. This trade represents a 1.15 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

SI-BONE Price Performance

Shares of SIBN opened at $13.47 on Tuesday. SI-BONE, Inc. has a 52-week low of $11.70 and a 52-week high of $19.16. The company has a market capitalization of $571.84 million, a PE ratio of -14.64 and a beta of 1.02. The stock has a fifty day simple moving average of $16.09 and a two-hundred day simple moving average of $14.69. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22.

SI-BONE (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, February 24th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The firm had revenue of $49.00 million during the quarter, compared to analyst estimates of $48.87 million. As a group, equities analysts forecast that SI-BONE, Inc. will post -0.78 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on SIBN shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 price objective on shares of SI-BONE in a research note on Tuesday, February 25th. Needham & Company LLC raised their price target on shares of SI-BONE from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Tuesday, February 25th. Finally, Truist Financial restated a “buy” rating and set a $22.00 price target (up from $18.00) on shares of SI-BONE in a research report on Tuesday, February 25th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $24.40.

Institutional Trading of SI-BONE

Hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC lifted its holdings in SI-BONE by 103.6% in the third quarter. FMR LLC now owns 2,354 shares of the company’s stock valued at $33,000 after acquiring an additional 1,198 shares during the last quarter. Virtus Fund Advisers LLC acquired a new position in shares of SI-BONE in the 4th quarter valued at $40,000. Mainstream Capital Management LLC acquired a new position in shares of SI-BONE in the 4th quarter valued at $53,000. GAMMA Investing LLC grew its holdings in shares of SI-BONE by 20,352.6% during the 1st quarter. GAMMA Investing LLC now owns 3,886 shares of the company’s stock worth $55,000 after purchasing an additional 3,867 shares during the period. Finally, R Squared Ltd acquired a new stake in shares of SI-BONE during the 4th quarter worth about $73,000. Institutional investors and hedge funds own 98.11% of the company’s stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.